Drugs / Tecadenoson
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00713401 | Feb → Apr 2008 | atrial fibrillation | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tecadenoson | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00713401 ↗ |
| Known as | CVT-510 | ChEMBL registry synonym — accepted as the source's own label CHEMBL392149 ↗ |
| Action | Activate | “a selective A1-adenosine receptor agonist tecadenoson” PMID 23989533 ↗ Aug 20131“Adenosine A1 receptor agonist” CHEMBL392149 ↗ |
| Modality | Small molecule | — CHEMBL392149 ↗ |
| Route | Intravenous | “Tecadenoson administered intravenously (i.v.)” NCT00713401 ↗ |
| Target | ADORA1 | “Adenosine A1 receptor agonist” CHEMBL392149 ↗ |